rss
05-22-2015, 09:52 PM
Asthma Therapeutics In Major Developed Market to a projected value of $21.7 billion by 2020: MarketResearchReports.biz
Asthma Therapeutics in Major Developed Markets to 2020 (http://www.marketresearchreports.biz/analysis/275426) Personalized Treatment for Severe Asthma to Drive Market Growth despite Patent Expirations””.The asthma therapeutics market is forecast to grow marginally over the forecast period across the top eight developed nations, from $18.4 billion in 2013 to a projected value of $21.7 billion by 2020 at a Compound Annual Growth Rate (CAGR) of 2.4%. This is in spite of generic erosion facing several of the leading asthma brands, such as Advair (fluticasone propionate/salmeterol xinafoate), Symbicort (budesonide/formoterol fumarate) and Xolair (omalizumab), and is a consequence of new market entrants and rising disease prevalence.
The global prevalence of asthma is significant, believed to affect approximately 300 million people worldwide. This burden is predicted to increase in future, reaching 400 million by 2025.
Download Detail Report With Complete TOC at*http://www.marketresearchreports.biz/sample/sample/275426 (http://www.marketresearchreports.biz/sample/sample/275426)
Although the majority of asthma patients are able to manage their symptoms effectively using currently marketed products, some remain inadequately controlled with these same products. This unmet need, coupled with rising global prevalence, has resulted in strong industry interest.
Consequently, the current asthma pipeline is highly in**vative, featuring several promising molecules in late-stage drug development. Biologics and mo**clonal antibodies, the latter in particular, are gaining prominence within the indication. **vel mo**clonal antibodies such as mepolizumab, reslizumab, lebrikizumab, and dupilumab target Interleukins (IL), or IL receptors, and have demonstrated potential in severe and inadequately controlled eosi**philic asthma, in turn representing a shift towards personalized therapy. Despite the fact that they target only a small patient sub-set, they are likely to be priced highly and to drive market growth, offsetting the impact of generic erosion.
Scope
The report covers and includes
An introduction to asthma, including discussion of disease epidemiology, etiology pathophysiology, symptoms, diag**sis, and treatment, with clinical data for ***** featured in the current treatment algorithm discussed in detail
In-depth analysis of the current marketed products landscape, including product profiles of the main ***** used and heat maps that compare their safety and efficacy parameters
Comprehensive analysis of the asthma pipeline by phase of development, molecule type, and molecular target and **velty, and comparative analysis of the most promising late-stage pipeline *****, as well as heat maps and a competitor matrix that compares safety and efficacy parameters
Additional in-depth analysis of the asthma clinical trials landscape, including trends in size, duration and failure rate
Forecast projections for the asthma market to 2020, including analysis of the global market and each of the eight major markets and incorporating projected, low, and high-variance scenarios based on treatment usage patterns and annual cost of therapy in each of the major markets
Discussion of the strategic consolidations landscape, including trends in co-development and licensing deals relevant to asthma drug products
Reasons to buy
The report will assist business development and enable marketing executives to strategize their product launches by allowing them to
Gain a comprehensive understanding of asthma, including diag**sis, disease severity, and treatment algorithms
Understand the current asthma marketed products landscape and recognize the dominant therapeutic agents and pharmaceutical players involved
Identify trends, developments, and prominent molecule types and molecular targets within the asthma pipeline
Gain an appreciation of the clinical and commercial aspects of the most promising late-stage pipeline molecules and their potential competitive impact on the future market
Consider market opportunities and potential risks by examining trends in asthma clinical trial size, duration and failure rate, phase of development, molecule type, and molecular target
Observe projections for treatment usage patterns, annual therapy costs, and market growth in the eight major markets and understand reasons for variance in projected patterns of growth
About MarketResearchReports.biz
Marketresearchreports.biz (http://www.marketresearchreports.biz/) is the most comprehensive collection of market research reports, supporting clients’ market intelligence needs with over 100,000 market research reports, company profiles, data books, and regional market profits in its repository. We also offer consulting support for custom market research needs.Our document database is updated by the hour, which means that our customers always have access to fresh data spanning over 300 industries. From Fortune 500 companies to SMEs, Marketresearchreports.biz has built a veritable reputation for fulfilling the most exacting market research needs.
Contact:
Toll Free: 866-997-4948
(USA-CANADA)
Tel: +1-518-618-1030
E: [email protected]
The post Asthma Therapeutics In Major Developed Market to a projected value of $21.7 billion by 2020: MarketResearchReports.biz (http://www.medgadget.com/2015/05/asthma-therapeutics-major-developed-market-projected-value-21-7-billion-2020-marketresearchreports-biz.html) appeared first on Medgadget (http://www.medgadget.com).
http://feeds.feedburner.com/~ff/Medgadget?d=yIl2AUoC8zA (http://feeds.feedburner.com/~ff/Medgadget?a=-rvxOjEFZUE:mvrr_3aJbq4:yIl2AUoC8zA) http://feeds.feedburner.com/~ff/Medgadget?d=qj6IDK7rITs (http://feeds.feedburner.com/~ff/Medgadget?a=-rvxOjEFZUE:mvrr_3aJbq4:qj6IDK7rITs) http://feeds.feedburner.com/~ff/Medgadget?i=-rvxOjEFZUE:mvrr_3aJbq4:gIN9vFwOqvQ (http://feeds.feedburner.com/~ff/Medgadget?a=-rvxOjEFZUE:mvrr_3aJbq4:gIN9vFwOqvQ)
http://feeds.feedburner.com/~r/Medgadget/~4/-rvxOjEFZUE
Asthma Therapeutics in Major Developed Markets to 2020 (http://www.marketresearchreports.biz/analysis/275426) Personalized Treatment for Severe Asthma to Drive Market Growth despite Patent Expirations””.The asthma therapeutics market is forecast to grow marginally over the forecast period across the top eight developed nations, from $18.4 billion in 2013 to a projected value of $21.7 billion by 2020 at a Compound Annual Growth Rate (CAGR) of 2.4%. This is in spite of generic erosion facing several of the leading asthma brands, such as Advair (fluticasone propionate/salmeterol xinafoate), Symbicort (budesonide/formoterol fumarate) and Xolair (omalizumab), and is a consequence of new market entrants and rising disease prevalence.
The global prevalence of asthma is significant, believed to affect approximately 300 million people worldwide. This burden is predicted to increase in future, reaching 400 million by 2025.
Download Detail Report With Complete TOC at*http://www.marketresearchreports.biz/sample/sample/275426 (http://www.marketresearchreports.biz/sample/sample/275426)
Although the majority of asthma patients are able to manage their symptoms effectively using currently marketed products, some remain inadequately controlled with these same products. This unmet need, coupled with rising global prevalence, has resulted in strong industry interest.
Consequently, the current asthma pipeline is highly in**vative, featuring several promising molecules in late-stage drug development. Biologics and mo**clonal antibodies, the latter in particular, are gaining prominence within the indication. **vel mo**clonal antibodies such as mepolizumab, reslizumab, lebrikizumab, and dupilumab target Interleukins (IL), or IL receptors, and have demonstrated potential in severe and inadequately controlled eosi**philic asthma, in turn representing a shift towards personalized therapy. Despite the fact that they target only a small patient sub-set, they are likely to be priced highly and to drive market growth, offsetting the impact of generic erosion.
Scope
The report covers and includes
An introduction to asthma, including discussion of disease epidemiology, etiology pathophysiology, symptoms, diag**sis, and treatment, with clinical data for ***** featured in the current treatment algorithm discussed in detail
In-depth analysis of the current marketed products landscape, including product profiles of the main ***** used and heat maps that compare their safety and efficacy parameters
Comprehensive analysis of the asthma pipeline by phase of development, molecule type, and molecular target and **velty, and comparative analysis of the most promising late-stage pipeline *****, as well as heat maps and a competitor matrix that compares safety and efficacy parameters
Additional in-depth analysis of the asthma clinical trials landscape, including trends in size, duration and failure rate
Forecast projections for the asthma market to 2020, including analysis of the global market and each of the eight major markets and incorporating projected, low, and high-variance scenarios based on treatment usage patterns and annual cost of therapy in each of the major markets
Discussion of the strategic consolidations landscape, including trends in co-development and licensing deals relevant to asthma drug products
Reasons to buy
The report will assist business development and enable marketing executives to strategize their product launches by allowing them to
Gain a comprehensive understanding of asthma, including diag**sis, disease severity, and treatment algorithms
Understand the current asthma marketed products landscape and recognize the dominant therapeutic agents and pharmaceutical players involved
Identify trends, developments, and prominent molecule types and molecular targets within the asthma pipeline
Gain an appreciation of the clinical and commercial aspects of the most promising late-stage pipeline molecules and their potential competitive impact on the future market
Consider market opportunities and potential risks by examining trends in asthma clinical trial size, duration and failure rate, phase of development, molecule type, and molecular target
Observe projections for treatment usage patterns, annual therapy costs, and market growth in the eight major markets and understand reasons for variance in projected patterns of growth
About MarketResearchReports.biz
Marketresearchreports.biz (http://www.marketresearchreports.biz/) is the most comprehensive collection of market research reports, supporting clients’ market intelligence needs with over 100,000 market research reports, company profiles, data books, and regional market profits in its repository. We also offer consulting support for custom market research needs.Our document database is updated by the hour, which means that our customers always have access to fresh data spanning over 300 industries. From Fortune 500 companies to SMEs, Marketresearchreports.biz has built a veritable reputation for fulfilling the most exacting market research needs.
Contact:
Toll Free: 866-997-4948
(USA-CANADA)
Tel: +1-518-618-1030
E: [email protected]
The post Asthma Therapeutics In Major Developed Market to a projected value of $21.7 billion by 2020: MarketResearchReports.biz (http://www.medgadget.com/2015/05/asthma-therapeutics-major-developed-market-projected-value-21-7-billion-2020-marketresearchreports-biz.html) appeared first on Medgadget (http://www.medgadget.com).
http://feeds.feedburner.com/~ff/Medgadget?d=yIl2AUoC8zA (http://feeds.feedburner.com/~ff/Medgadget?a=-rvxOjEFZUE:mvrr_3aJbq4:yIl2AUoC8zA) http://feeds.feedburner.com/~ff/Medgadget?d=qj6IDK7rITs (http://feeds.feedburner.com/~ff/Medgadget?a=-rvxOjEFZUE:mvrr_3aJbq4:qj6IDK7rITs) http://feeds.feedburner.com/~ff/Medgadget?i=-rvxOjEFZUE:mvrr_3aJbq4:gIN9vFwOqvQ (http://feeds.feedburner.com/~ff/Medgadget?a=-rvxOjEFZUE:mvrr_3aJbq4:gIN9vFwOqvQ)
http://feeds.feedburner.com/~r/Medgadget/~4/-rvxOjEFZUE